Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142480 · ClinicalTrials.gov registry record · Phase 2
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer
A Phase 2 study of Biliary Tract Cancer and Gallbladder Adenocarcinoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 3
- Study locations
NCT00142480: Completed Phase 2 study of Biliary Tract Cancer and Gallbladder Adenocarcinoma, sponsored by Massachusetts General Hospital.
NCT00142480 is a Phase 2 study of Biliary Tract Cancer and Gallbladder Adenocarcinoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 8 participants, below the 239-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00142480, a Phase 2 study of Biliary Tract Cancer and Gallbladder Adenocarcinoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main purpose of this study is to test the safety and effectiveness of oxaliplatin, bevacizumab, and capecitabine given in combination with radiation therapy to see what effects (good or bad) they have on patients with biliary tract and gallbladder cancer.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- DRUG Oxaliplatin
- PROCEDURE Radiation therapy
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-12 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
What the finished NCT00142480 record still lists
NCT00142480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 239-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Biliary Tract Cancer appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00142480 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00142480 about?
NCT00142480 is a clinical study titled "Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer". The main purpose of this study is to test the safety and effectiveness of oxaliplatin, bevacizumab, and capecitabine given in combination with radiation therapy to see what effects (good or bad) they have on patients with biliary tract and gallbladder cancer.
What is the current status of trial NCT00142480?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2004-12. Estimated completion is 2011-04.
What conditions does trial NCT00142480 study?
This clinical trial studies the following conditions: Biliary Tract Cancer, Gallbladder Adenocarcinoma.
What interventions are being tested in trial NCT00142480?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Oxaliplatin (DRUG), Radiation therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00142480?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00142480 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00142480's enrollment target sits among peer trials
8 37th of 36 the lowest of 36 other Biliary Tract Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Biliary Tract Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
RECRUITING · Phase 2
-
Ligufalimab and Cadonilimab in Advanced Liver Cancers
RECRUITING · Phase 2
-
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia